Table 2.
Vaccination schedule and vaccine effectiveness against infection, by combination and period. Values are numbers (percentages) unless stated otherwise
| Overall (n=150 966) | 3-11 years old (n=59 858) | 12-17 years old (n=91 108) | Vaccine effectiveness (95% CI) | ||
|---|---|---|---|---|---|
| Delta period | Omicron period | ||||
| Cases | 73 409 (48.6) | 29 200 (48.8) | 44 209 (48.5) | - | - |
| Vaccination schedule | |||||
| mRNA-1273 and mRNA-1273 | 22 141 (14.7) | 0 (0.0) | 22 141 (24.3) | 70.2 (66.8 to 73.1) | 17.9 (14.0 to 21.5) |
| mRNA-1273 and BNT162b2 | 4197 (2.8) | 0 (0.0) | 4197 (4.6) | 66.3 (54.0 to 75.4) | 31.5 (26.3 to 36.4) |
| BNT162b2 and mRNA-1273 | 573 (0.4) | 0 (0.0) | 573 (0.6) | 88.9 (66.1 to 96.4) | 40.6 (29.4 to 50.0) |
| BNT162b2 and BNT162b2 | 64 197 (42.5) | 0 (0.0) | 64 197 (70.5) | 64.1 (60.5 to 67.3) | 28.1 (25.2 to 30.8) |
| BBIBP-CorV and BBIBP-CorV | 59 858 (39.6) | 59 858 (100.0) | 0 (0.0) | 61.2 (56.4 to 65.6) | 16.0 (13.2 to 18.6) |
CI=confidence interval.